Intravitreal bevacizumab for uveitic choroidal neovascularization.
To report 5 cases of inflammatory choroidal neovascularization (CNV) that were treated with intravitreal bevacizumab. Six eyes of 5 patients with uveitic CNV were treated with 2.5 mg/0.1 mL of intravitreal bevacizumab. Main outcome measures were the changes in BCVA and reduction in the size of the CNV. The mean follow-up time was 15.3 months. The mean intravitreal injections administered were 2.7. All patients showed a reduction in the size of the CNV with improvement in BCVA in 60% of cases at the last follow-up. Intravitreal bevacizumab may provide an additional strategy in the management of inflammatory CNV.